Cargando…

Discovering New Medicines Targeting Helicases: Challenges and Recent Progress

Helicases are ubiquitous motor proteins that separate and/or rearrange nucleic acid duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases encoded by bacteria, viruses, and human cells are widely studied targets for new antiviral, antibiotic, and anticancer drugs. This re...

Descripción completa

Detalles Bibliográficos
Autores principales: Shadrick, William R., Ndjomou, Jean, Kolli, Rajesh, Mukherjee, Sourav, Hanson, Alicia M., Frick, David N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Laboratory Automation and Screening. Published by Elsevier Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427233/
https://www.ncbi.nlm.nih.gov/pubmed/23536547
http://dx.doi.org/10.1177/1087057113482586
_version_ 1782370697566224384
author Shadrick, William R.
Ndjomou, Jean
Kolli, Rajesh
Mukherjee, Sourav
Hanson, Alicia M.
Frick, David N.
author_facet Shadrick, William R.
Ndjomou, Jean
Kolli, Rajesh
Mukherjee, Sourav
Hanson, Alicia M.
Frick, David N.
author_sort Shadrick, William R.
collection PubMed
description Helicases are ubiquitous motor proteins that separate and/or rearrange nucleic acid duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases encoded by bacteria, viruses, and human cells are widely studied targets for new antiviral, antibiotic, and anticancer drugs. This review summarizes the biochemistry of frequently targeted helicases. These proteins include viral enzymes from herpes simplex virus, papillomaviruses, polyomaviruses, coronaviruses, the hepatitis C virus, and various flaviviruses. Bacterial targets examined include DnaB-like and RecBCD-like helicases. The human DEAD-box protein DDX3 is the cellular antiviral target discussed, and cellular anticancer drug targets discussed are the human RecQ-like helicases and eIF4A. We also review assays used for helicase inhibitor discovery and the most promising and common helicase inhibitor chemotypes, such as nucleotide analogues, polyphenyls, metal ion chelators, flavones, polycyclic aromatic polymers, coumarins, and various DNA binding pharmacophores. Also discussed are common complications encountered while searching for potent helicase inhibitors and possible solutions for these problems.
format Online
Article
Text
id pubmed-4427233
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Society for Laboratory Automation and Screening. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-44272332015-05-11 Discovering New Medicines Targeting Helicases: Challenges and Recent Progress Shadrick, William R. Ndjomou, Jean Kolli, Rajesh Mukherjee, Sourav Hanson, Alicia M. Frick, David N. SLAS Discov Review Article Helicases are ubiquitous motor proteins that separate and/or rearrange nucleic acid duplexes in reactions fueled by adenosine triphosphate (ATP) hydrolysis. Helicases encoded by bacteria, viruses, and human cells are widely studied targets for new antiviral, antibiotic, and anticancer drugs. This review summarizes the biochemistry of frequently targeted helicases. These proteins include viral enzymes from herpes simplex virus, papillomaviruses, polyomaviruses, coronaviruses, the hepatitis C virus, and various flaviviruses. Bacterial targets examined include DnaB-like and RecBCD-like helicases. The human DEAD-box protein DDX3 is the cellular antiviral target discussed, and cellular anticancer drug targets discussed are the human RecQ-like helicases and eIF4A. We also review assays used for helicase inhibitor discovery and the most promising and common helicase inhibitor chemotypes, such as nucleotide analogues, polyphenyls, metal ion chelators, flavones, polycyclic aromatic polymers, coumarins, and various DNA binding pharmacophores. Also discussed are common complications encountered while searching for potent helicase inhibitors and possible solutions for these problems. Society for Laboratory Automation and Screening. Published by Elsevier Inc. 2013-08 2022-04-25 /pmc/articles/PMC4427233/ /pubmed/23536547 http://dx.doi.org/10.1177/1087057113482586 Text en Copyright © 2013 Society for Laboratory Automation and Screening. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Shadrick, William R.
Ndjomou, Jean
Kolli, Rajesh
Mukherjee, Sourav
Hanson, Alicia M.
Frick, David N.
Discovering New Medicines Targeting Helicases: Challenges and Recent Progress
title Discovering New Medicines Targeting Helicases: Challenges and Recent Progress
title_full Discovering New Medicines Targeting Helicases: Challenges and Recent Progress
title_fullStr Discovering New Medicines Targeting Helicases: Challenges and Recent Progress
title_full_unstemmed Discovering New Medicines Targeting Helicases: Challenges and Recent Progress
title_short Discovering New Medicines Targeting Helicases: Challenges and Recent Progress
title_sort discovering new medicines targeting helicases: challenges and recent progress
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427233/
https://www.ncbi.nlm.nih.gov/pubmed/23536547
http://dx.doi.org/10.1177/1087057113482586
work_keys_str_mv AT shadrickwilliamr discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress
AT ndjomoujean discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress
AT kollirajesh discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress
AT mukherjeesourav discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress
AT hansonaliciam discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress
AT frickdavidn discoveringnewmedicinestargetinghelicaseschallengesandrecentprogress